Literature DB >> 6986939

Clomipramine and exposure for obsessive-compulsive rituals: i.

I M Marks, R S Stern, D Mawson, J Cobb, R McDonald.   

Abstract

Forty chronic obsessive-compulsive ritualizers were randomly assigned to treatment with oral clomipramine or placebo for 8 months. During weeks 4 to 7 these two groups were each randomly split into treatment by relaxation or by exposure in vivo, and during weeks 7 to 10 all patients had exposure in vivo. Double blind assessments were made at weeks 4, 7, 10, 18, 36, 62 and 114. Results are reported to one year. Clomipramine produced significant improvement in rituals, mood and social adjustment, but only in those patients who initially had depressed mood. The clomipramine effect was maximum from weeks 10 to 18 and diminished thereafter. On stopping clomipramine patients often relapsed and improved again on restarting the drug. Relaxation produced little change. Exposure produced significant lasting improvement in rituals, but less change in mood; improvement generalized to social adjustment at follow-up. Clomipramine plus exposure had a slight additive but not interactional effect. Clomipramine enhanced compliance both with exposure and with relaxation. Clomipramine is useful for compulsive ritualizers with depressed mood, but may need continuation for over a year and combination with exposure in vivo. Exposure in vivo remains the treatment of choice for rituals without depressed mood.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6986939     DOI: 10.1192/bjp.136.1.1

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  22 in total

Review 1.  A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder.

Authors:  Dan J Stein; Nastassja Koen; Naomi Fineberg; Leonardo F Fontenelle; Hisato Matsunaga; David Osser; H Blair Simpson
Journal:  Curr Psychiatry Rep       Date:  2012-06       Impact factor: 5.285

Review 2.  Serotonin selectivity for obsessive compulsive and panic disorders.

Authors:  S A Montgomery; T Bullock; N Fineberg
Journal:  J Psychiatry Neurosci       Date:  1991-07       Impact factor: 6.186

3.  Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial.

Authors:  Michael Rufer; Iver Hand; Heike Alsleben; Anne Braatz; Jürgen Ortmann; Birgit Katenkamp; Susanne Fricke; Helmut Peter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

Review 4.  Cognitive behavioral therapy for obsessive-compulsive disorder: an update.

Authors:  Jonathan D Huppert; Martin E Franklin
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

5.  The classification of depression.

Authors:  E S Paykel
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

6.  Drug treatment of obsessive-compulsive disorder.

Authors:  P T Lelliott; W O Monteiro
Journal:  Drugs       Date:  1986-01       Impact factor: 9.546

7.  Sleep EEG of patients with obsessive-compulsive disorder.

Authors:  F Hohagen; S Lis; S Krieger; G Winkelmann; D Riemann; R Fritsch-Montero; E Rey; J Aldenhoff; M Berger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

8.  D-amphetamine in obsessive-compulsive disorder.

Authors:  T R Insel; J A Hamilton; L B Guttmacher; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

9.  Clomipramine in obsessive-compulsive ritualisers treated with exposure therapy: relations between dose, plasma levels, outcome and side effects.

Authors:  Y Kasvikis; I M Marks
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 10.  Current concepts in the pharmacological treatment of obsessive-compulsive disorder.

Authors:  J Zohar; R C Zohar-Kadouch; S Kindler
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.